Evidence map›Paper›PMID 39269476›Full record

ArticleAnnals of hematology2025

Treatment-related leukoencephalopathy in adults with central nervous system lymphoma: a retrospective analysis of 126 patients.

Yasutaka Masuda, Katsuhiko Nara, Alice Fujii-Mori, Arika Shimura, Kazuki Taoka, Takeyuki Watadani, Ken Morita, Takehito Yamamoto, Mineo Kurokawa, Tappei Takada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yasutaka Masuda *Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8404-3208
Katsuhiko Nara *Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Alice Fujii-MoriDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
Arika ShimuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kazuki TaokaClinical Application for Development of Therapy for Rare Disease, The University of Tokyo Hospital, Tokyo, Japan.
Takeyuki WatadaniDepartment of Radiology, The University of Tokyo Hospital, Tokyo, Japan.
Ken MoritaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takehito YamamotoDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan. takehitoyamamoto@g.ecc.u-tokyo.ac.jp.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotoxicity associated with high-dose chemotherapy and whole brain radiotherapy (WBRT) is one of major complications for patients with central nervous system lymphoma (CNSL). Here we determined the incidence and risk factors of treatment-related leukoencephalopathy (tLE) in a clinical setting. We retrospectively reviewed clinical and radiological findings of 126 patients with  (CNSL) treated with high-dose methotrexate with or without intrathecal methotrexate administration (IT MTX) and response-adapted WBRT. During the whole observation period with a median of 38.7 months, tLE was found in 33 patients, most of them asymptomatic, with the median time to development 3.0 months, and the cumulative incidence reaching 29.2% (95% confidence interval, 20.6-38.2%) two years post chemotherapy. By multivariable analysis, IT MTX was identified as the only one significant risk factor (hazard ratio, 4.50; P < 0.001), and the number of IT MTX was associated with the increased incidence and severity of tLE. These findings highlight the frequent neurological complications associated with CNS-directed therapy and confirm the neurotoxicity of IT MTX.

Indexed as

Central Nervous System NeoplasmsLeukoencephalopathiesLymphomaMethotrexateAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCranial IrradiationFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAntimetabolites, AntineoplasticMethotrexateCentral nervous system lymphomaHigh-dose methotrexateIntrathecal methotrexateLeukoencephalopathyVitreoretinal lymphoma

Identifiers

PMID39269476
PMCPMC11971226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.